Get notified when SRPT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Ceo (new) — Current CEO Douglas Ingram is departing his executive and board positions effective July 28, 2026, described as a retirement with advisory role through year-end.
Sarepta appoints Michael Severino as CEO with $35M equity grant; Doug Ingram retires
Filed July 27, 2026 · Period ending July 23, 2026 · ~1 min read
Key Changes
-
high
Michael Severino, M.D., appointed CEO effective July 28, 2026, with $1.18M base salary, 110% target bonus, and $35M sign-on equity grant including $14M make-whole for forfeited prior-employer awards.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Doug Ingram departs as CEO and board member July 28, 2026, transitioning to consultant through year-end at $15,000 monthly fee.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Severino brings 25+ years biopharmaceutical experience, most recently CEO of Tessera Therapeutics and previously Vice Chairman/President at AbbVie overseeing R&D and corporate strategy.
Exhibit 99.1 view on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (INTC 10-Q) is open in full — no account needed.
Partner
Trade SRPT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify